Recep Tayyip Erdoğan University Training and Research Hospital, Pathology Department - Rize, Turkey.
Recep Tayyip Erdoğan University Training and Research Hospital, Biochemistry Department - Rize, Turkey.
Rev Assoc Med Bras (1992). 2022 Feb;68(2):227-233. doi: 10.1590/1806-9282.20210979.
The stroma surrounding the tumor cells is important in tumor progression and treatment resistance, besides the properties of tumor cells. Studies on the tumor stroma characteristics will contribute to the knowledge for new treatment approaches.
A total of 363 breast cancer patients were evaluated for the tumor-stroma ratio. The percentage of stroma was visually assessed on hematoxylin-eosin stained slides. The cases of tumor-stroma ratio more than 50% were categorized as tumor-stroma ratio high, and those less than 50% and below were categorized as tumor-stroma ratio low.
Tumor-stroma ratio-high tumors had shorter overall survival (p=0.002). Disease-free survival tended to be shorter in tumor-stroma ratio-high tumors (p=0.082) compared with tumor-stroma ratio-low tumors. Tumor-stroma ratio was an independent prognostic parameter for the total group of patients (p=0.003) and also axillary lymph node metastasis and tumor-stroma ratio was statistically associated (p=0.004). Also, tumor-stroma ratio was an independent prognostic parameter in node-positive Luminal A and B subgroups for overall survival (p<0.001).
Tumor-stroma ratio is an independent prognostic parameter that can be evaluated quite easily in all molecular subtypes of all breast cancers and does not require extra cost and time to evaluate.
肿瘤细胞周围的基质在肿瘤进展和治疗耐药性方面很重要,除了肿瘤细胞的特性。对肿瘤基质特征的研究将有助于为新的治疗方法提供知识。
共评估了 363 例乳腺癌患者的肿瘤-基质比。在苏木精-伊红染色切片上通过目测评估基质的百分比。将肿瘤-基质比大于 50%的病例归类为肿瘤-基质比高,而小于 50%和低于 50%的病例归类为肿瘤-基质比低。
肿瘤-基质比高的肿瘤总生存时间较短(p=0.002)。与肿瘤-基质比低的肿瘤相比,肿瘤-基质比高的肿瘤无病生存时间更短(p=0.082)。肿瘤-基质比是所有患者总体的独立预后参数(p=0.003),也是腋窝淋巴结转移和肿瘤-基质比的统计学关联(p=0.004)。此外,肿瘤-基质比是淋巴结阳性 Luminal A 和 B 亚组总生存的独立预后参数(p<0.001)。
肿瘤-基质比是一个独立的预后参数,可以在所有乳腺癌的所有分子亚型中相当容易地评估,并且不需要额外的成本和时间来评估。